Urodynamix Launches uroNIRS 2000(TM) Pilot Program With Cardinal Health

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announces that it has
commenced a pilot sales and marketing program with Cardinal Health for its
uroNIRS 2000, an innovative technology for the non-invasive diagnosis of bladder
conditions. The 90-day pilot program will be used to by Urodynamix and Cardinal
Health to evaluate the viability of adding the uroNIRS 2000 to Cardinal Health's
catalogue of offerings to the urology market.


The uroNIRS 2000 provides a real-time, non-invasive evaluation of the bladder
function during voiding to aid in the diagnosis of bladder outlet obstruction.
The product is approved for sale in the U.S.


About Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd. is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic
hyperplasia, and traumatic increases in intra-abdominal pressure that cause
abdominal compartment syndrome. Urodynamix's breakthrough medical technology has
the potential to beneficially affect more than 200 million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.